



# 美洲華人生物科學學會

*Society of Chinese Bioscientists in America (SCBA)*

## Bio/Pharm Division

Sept, 2005

**Newsletter**

Volume 13

Issue 2

### Past & current events

- On June 18, 2005, Chi-Ming Lee and several Bio/Pharm council members have attended, as honored guests, the 3rd SAPA-GP Annual Conference: **Globalization of Pharmaceutical/Biotech R&D**. The meeting was a great success with lively discussions, and most of the several hundred participants stayed till the end of the meeting. Some interesting slide presentations are available on SAPA website <http://www.sapa-gp.org/>.
- On July 31, Chi-Ming Lee hosted a Tele-conference with 3 executives from SAPA-West to discuss co-sponsorship of the Biotech & Biopharm theme at the SCBA 2006 Biennial SCBA conference. The conference will take place at Hyatt Regency in San Francisco from July 19 (Wednesday) to July 23 (Sunday), 2006. Kenneth Fong and Mien-Chie Hung will co-chair the 11<sup>th</sup> SCBA International Symposium. Please mark your calendar and stay tuned for more information.
- On Sept. 10, 2005, Chi-Ming Lee attended SAPA-GP annual picnic and discussed with the president of SAPA-GP on future collaborations.
- After many tele-conferences, the SCBA Bio/Pharm operating council and Annual Meeting organizing committee met face-to-face on Sept. 17, 2005 in Rutgers University to fine-tune the program, logistics and

promotion of our annual conference scheduled on Dec. 4, 2005. Please see conference announcement below.

### Upcoming events:

- **Dec. 4 2005: SCBA Bio/Pharm Annual Conference**

**“Tackling the Challenges in Pharmaceutical Research, Development and Commercialization”**

[December 4, 2005, Sunday, 9am to 6pm](#)

**Rutgers University, Busch Campus Center, Piscataway, New Jersey**

The average cost for bringing a drug to market is \$850 million today. This is up from \$500 million in 1990 and \$350 million in 1980. In spite of increasing investment in Pharma R&D, the number of new drugs approved has been declining in recent years. The purpose of the 2005 BioPharm annual conference is to tackle the pharma productivity issue. It will provide the participants a forum to understand and discuss various approaches being used to increase productivity in the preclinical, clinical and business development arena. The program includes several keynote speeches to be presented by prominent leaders in the field, Dr Ray Lipicky, former Director of Cardiorenal Division at FDA, Dr Paul Chew, VP of Metabolism and Thrombosis at Sanofi-Aventis, Dr Henry Pan, Chief Medical Officer at

Neurocrine Biosciences and Prof. Yung-Chi Cheng at Yale University.

There will be four parallel lecture tracks with over 40 speakers covering the following key areas of interest:

Application of Genomics and Proteomics in Pharmaceutical Industry

Medicinal chemistry & ADMET

Animal Disease Models

Biomarkers/ Translational Medicine

Clinical Research – Operational Aspects

Clinical Trials and Statistical Consideration

Today's Regulatory Environment

Business Development

Public Relations/Health Authority/ Third Party Payers

Career Development

#### Conference Co-Chair

Frank Jiang, MD, PhD  
Sanofi-Aventis

Lu Cui, PhD  
Sanofi-Aventis

#### Local Organizing Committee

Longqin Hu, Ph.D. (Chair)  
Rutgers University

Hong-son Cheung

Laishun Chen, PhD  
Bristol-Myers Squibb Inc.

Tony Kong, Ph.D.  
Rutgers University

Siang-yo Lin  
Lin & Lin Financial Services

Yen-Huei Lin, Ph.D  
Wyeth Research

#### Conference Promotion

Jay Liu, Ph.D  
AstraZeneca Pharmaceuticals LP

Junfang Li, Ph.D  
Sanofi-Aventis

#### Treasury & Fund Raising

Paul Hsia  
China Health Group  
Stephen Wong, PhD

Pfizer Inc

#### Advisory Committee

Shing Chang, Ph.D  
Abbott Laboratories

Yung-Chi Cheng, Ph.D  
Yale University

Nehemiah Cherng, Ph.D.  
EastWest Pharma

Chi-Ming Lee, Ph.D  
AstraZeneca Pharmaceuticals LP

Wei-Chi Liao, Ph.D, M.D.  
Abbott Laboratories

Henry Pan, M.D.  
Neurocrine Biosciences

Chung S. Yang, Ph.D

Rutgers University

For more information, visit the conference website:  
<http://biopharm.us>

- **Oct 13-15 2005:**  
**Biofunding Summit 2005**

International Think-Tank Forum on  
Anti-Cancer Innovations and Global  
Collaborations

Peking Union Medical College  
Beijing, China

For more information, visit  
<http://www.biofundingsummit.com/>

- **Oct. 1, 2005, 10am-4pm:**  
**American Chinese  
Pharmaceutical Association  
(ACPA) regional conference**

Biopharmaceutical Comparability

University of Maryland Shady Grove Center  
9630 Gudelsky Drive, Rockville, MD 20850

For more information, visit  
<http://www.acpa-rx.org/whatsnew.htm>

- **July 20-23, 2006:**  
**SCBA Biennial Conference**

Hyatt Regency Hotel, San Francisco, CA

For more information, visit <http://www.scba-society.org>

The SCBA Bio/Pharm Operating council 2005:

**President:** Chi-Ming Lee, AstraZeneca, 302-885-0669, [chi-ming.lee@astrazeneca.com](mailto:chi-ming.lee@astrazeneca.com)

**Conf. Planning:** Yen-Huei Lin, Wyeth Lab, 845-602-3879, [Liny3@wyeth.com](mailto:Liny3@wyeth.com)

**Membership:** Wen-lang Yang, A. Einstein Coll Med718-430-3772, [wlyang@nshs.edu](mailto:wlyang@nshs.edu)

**Website:** Lai-shun Chen, Bristol-Myers Squibb 609-252-4598 [chenls@yahoo.com](mailto:chenls@yahoo.com)

**Quarterly:** Lu-hai Wang, Mt. Sinai Med Ctr212-241-3795, [lu-hai.wang@mssm.edu](mailto:lu-hai.wang@mssm.edu)

**Fundraising:** Tong Kong, Rutgers Coll Pharm 732-445-7335, [KongT@rci.rutgers.edu](mailto:KongT@rci.rutgers.edu)

**Newsletter:** Jay Liu, AstraZeneca, 302-886-2667, [jay.liu@astrazeneca.com](mailto:jay.liu@astrazeneca.com)

**Finance:** Paul Hsia, China Health Gp, 630-865-3388, [pthsia@aol.com](mailto:pthsia@aol.com)

**Treasury:** Jason Chen, J. Chen & Asso. LLC, 732-846-6567, [jason@jasonchencpa.com](mailto:jason@jasonchencpa.com)